After $80 million, Fosun Pharma or $140 million to introduce new technology

Pharmaceuticals.com on January 18, Fosun Pharma held a strategic cooperation launch ceremony with Kite Pharma, announced that it will establish a joint venture with Kite Pharma in China to introduce its cancer treatment technology and products, to bring China's lymphoma patients to the world's leading treatmentearlier, Fosun Pharma announced that it would invest no more than $80 million in a joint venture with Kite to expand into the market for cancer T-cell immunotherapy in China, including Chinese mainland, Hong Kong and MacauThe first product to be introduced in this collaboration is KTE-C19 therapy, which is a research chimeric antigen receptor (CAR) T-cell therapy product for the treatment of relapsed refractory B-cell lymphoma and leukemia, and is currently in the clinical stage of research and developmentIn addition, Fosun Pharma will deepen its cooperation with Kite Bio, which is expected to introduce two other products, KITE-439 and KITE-718, which are still in the preclinical research and development phaseadded $14 0.
million to introduce two other technologies
Fosun Pharma to The Arterial Network (WeChat:vcbeat), said that the introduction of KTE-C19 therapy, one of the main indications of DLBCL (diffuse large B lymphocytosis): is one of the largest number of patients, aggressive, rapid progress of the disease of lymphoma subtype, and chemotherapy-resistant DLBLC patients clinical treatment options are very limited, historical data is very poorFrom the current data, the product can bring very significant results to patients, its clinical approval may be largeRisk factors are inevitable, but from the development of the last two years, Kite Pharma in cell therapy is the fastest progress, in addition to product-level cooperation after the establishment of the joint venture, the two sides will use their respective advantages, the joint venture company as China's leading tumor T cell therapy research and development and production platform, and constantly enhance their own research and development capabilities, closely follow the world's most advanced technology, step by step to hone their own strengthContinuous innovation is Fosun Pharma's long-held belief that we can handle even in the event of a riskFosun Pharma said in a January 12 announcement that in the future, the joint venture may continue to introduce Kite Pharma's follow-up products under study, including KITE-439, a TCR cell therapy product that expresses directly targeting HPV type 16 E7 cancer protein, and KITE-718So will the details of subsequent cooperation (including KTE-439, KTE-718) be similar to this round?We understand that within 7 years from the date of the establishment of the joint venture, with the unanimous consent of the board of directors of the new company, the preferred option may be exercised for any subsequent product (i.e., KITE-439 and KITE-718)Both products are currently in the preclinical development phase, and their specific therapeutic areas will depend on the developmentThe full cost to Kite (including licensing fees and all milestone payments, excluding sales commissions) to kite for subsequent products (i.eKITE-439 and KITE-718) is estimated at $14 million Other specific licenses for subsequent products (i.e KITE-439 and KITE-718) are subject to further consultation and agreement between the new company and Kite China is the world's second-largest pharmaceutical market outside the United States, according to data from the 's Gold Cancer Treatment Market With the rise in morbidity and mortality, cancer has become the number one killer in China's disease , with more than 4 million new cases and 2.8 million deaths from cancer each year The five-year survival rate of a variety of high-risk cancers in China is significantly lower than that of the United States, with nearly 40% of the survival rates of cervical cancer, lymphoma and leukemia According to the latest forecast, China's annual diagnosis of non-Hodgkin's lymphoma (NHL) cases close to 73,000 cases, of which the largest proportion of the type of diffuse large B cell lymphoma is one of the largest number of patients, very invasive, rapid development of lymphoma, difficult-to-treat patients have very limited clinical options, with a huge unmet needs Thus, Fosun Pharma's choice to introduce new technology into the field of cancer treatment in China can be understood as "market-for-technology", in addition to optimistic about the field of income-generating capacity, the cultivation of their own technology is also an important concept in fact, as early as 2009, Fosun Pharma on the layout of monoclonal antibody drug research and development, is now a domestic industry leader, in lymphoma, breast cancer and other cancer areas, Fosun Pharma monoclonal antibody research and development platform Fuhong Hanqi has made important progress in research and development, its first varieties of non-Hodgkin's lymphoma and the second varieties of breast cancer indications have entered the third stage of clinical stage The first introduction of KTE-C19 will be a strong complement to cd-ROM0 as a target monoclonal antibody drug, covering the entire B-cell lymphoma treatment phase, providing a complete solution for patients in China Kite Pharma has a number of cutting-edge research in the field of cell immunotherapy and has strong technical advantages, and Fosun Pharma's "joint development and priority commercialization power" will open the way for it to quickly open up its way to the Chinese market
"We are committed to providing cancer patients in China with the world's leading cancer immunocellular therapy technology," said Arie Belldegrun, Chairman, President and CEO of Kite Pharma Fosun Pharma is China's leading biopharmaceutical innovation company, is also an active market development company, is our ideal partner in China to promote the commercialization of KTE-C19 products We look forward to your joint efforts to meet the huge unmet treatment needs of the Chinese market "
" There are huge unmet needs in the field of cancer treatment in China, and this partnership with Kite Pharma is significant and marks an important and strategic step in Fosun Pharma's t-cell immunotherapy platform in China, helping us to provide the world's leading cancer treatment stools for patients in need "In addition, Kite Pharma's oncology immunocellular therapy products have significant synergies with Fosun Pharma's existing products," said Chen Qiyu, Chairman of Fosun Pharma "
fossing pharmaceutical technology introduction for the long-term in the field of biopharmaceutical technology "buy and buy" Fosun Pharma, this introduction is only the starting point of 2017 pharmaceutical investment and is not the end before Fosun Pharma has demonstrated its determination to invest in biopharmaceutical technology For example, in 2016, it paid $1,261 million to acquire an 86.08 percent stake in Indian injectable drugmaker Gland Pharma, the largest overseas acquisition by a Chinese pharmaceutical company last year, and in September 2016 Fosun Pharma set up a joint venture with Da Vinci robotics maker Intuitive, USA, to target robotically assisted technology innovation in the early diagnosis and treatment of lung cancer Fosun Pharma to Arterial Network (WeChat: vcbeat) said that innovative research and development has entered the era of precision medicine, Fosun Pharma in recent years continued to increase research and development investment, research and development innovation target series is gradually focused on this, especially in solving the problem of cancer, Fosun Pharma closely follow the global cutting-edge technology, is committed to providing patients with the most comprehensive, optimal treatment technology and treatment programs at the same time, Fosun Pharma is constantly exploring new cooperation models in the process of creating a closed loop for the cancer precision medical industry From the traditional product introduction model gradually try to cooperate in research and development, production and sales of the cooperative model, more involved in the world's leading technology research and development process At the end of 2016, Fosun Pharma and The Global Leader in Robotic assisted Microinvasive Surgery, The U.S Intuitive Medical Devices Company, announced the official launch of a strategic partnership to establish a joint venture in Shanghai
develop, produce and sell innovative products based on robotic-assisted catheter technology for early diagnosis and treatment of lung cancer This will provide doctors with innovative and accurate diagnostic tools to improve care for the benefit of lung cancer patients Chen Qiyu, chairman of Fosun Pharma, also said in public that Fosun Pharma has been in the overall transformation process in the last two years One is to make organizational change sriven by technological innovation, and the other is that the innovation model focuses on China and the United States Specifically, Fosun Pharma in the past in the pharmaceutical business more, through nearly 10 years, has formed a clear innovation line in the pharmaceutical business input, the future will continue to add code in the pharmaceutical innovation business; industry insiders said that from 2016 to this time with Kite, it is clear that Fosun Pharma in the biopharmaceutical technology layout logic, that is, to acquire or capital injection in the field of leading companies in the sub-sector, access to its technology, and then with their existing business layout, to enhance their own "blood-making" capabilities At the same time, foreign technology enterprises are also willing to cooperate with the revival, with the help of Fosun Pharma in the domestic resources, its products and technology can quickly land, Fosun Medicine actually acts as a "graft bridge" role, in the process, Fosun medicine can also benefit from it